Shares of Exact Sciences (one of our healthcare team's favorite longs) have surged over 10% today. The stock soared after UnitedHealth Group said it plans to cover the company's colon cancer test starting on July 1. EXAS was targeted by short-seller Citron Research earlier this month -- one of the short-seller's allegations was that UnitedHealth Group wouldn't ever cover the test.
Here's our response to Citron Research earlier this month.
https://twitter.com/KeithMcCullough/status/869915814127960068
Here's our Sector Head Tom Tobin discussing our long call back in January. The stock is up 100% since then.